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There are multiple hypotheses for the causes of the obesity epidemic. One 
such hypothesis is that dietary intake patterns have significantly shifted to include 
unprecedented amounts of refined sugar. We set out to determine some the unique 
metabolic changes that occur with initial exposure to dilute glucose, sucrose, high 
fructose corn syrup, or fructose solutions. Rats were given access to food, water and a 
sugar solution for 24 h, after which blood and tissues were collected. Fructose access 
(as opposed to other sugars investigated) resulted in a doubling of circulating 
triglycerides. Glucose consumption resulted in upregulation of 7 satiety related 
hypothalamic peptides whereas changes in gene expression were mixed for remaining 
sugars. Also, following multiple verification assays, 6 satiety related peptides were 
verified as being affected by sugar intake. These data provide evidence that not all 






















Thesis submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Professor Thomas W. Castonguay, Chair 
Arthur N. Popper 























© Copyright by 



















Thank you to the love of my life Bob for all the compassion, support and 
understanding. Without you, I wouldn‟t have made it. You are my greatest 
cheerleader. I love you. 
 
To Dr. C, thank you for being the world‟s greatest advisor! You have taught me so 
much I am so thankful for the impact you have made on my life. Thank you for 




Table of Contents 
Acknowledgements ....................................................................................................... ii 
 
Table of Contents ......................................................................................................... iii 
 
List of Tables ................................................................................................................ v 
 
List of Figures ............................................................................................................. vii 
 
List of Abbreviations ................................................................................................. viii 
 
Chapter 1: Literature Review ........................................................................................ 1 
Introduction ............................................................................................................... 2 
Amylin ...................................................................................................................... 4 
Agouti Related Peptide ............................................................................................. 5 
Cholecystokinin ........................................................................................................ 6 
Corticotrophin Releasing Hormone .......................................................................... 8 
Dopamine .................................................................................................................. 9 
Growth Hormone .................................................................................................... 10 
Neuropeptide Y ....................................................................................................... 11 
Receptor Activity Modifying Protein 3 .................................................................. 12 
Tumor Necrosis Factor ........................................................................................... 13 
Thyrotropin Releasing Hormone ............................................................................ 14 
 
Chapter 2: Effects of Sugar Solutions on Hypothalamic Appetite Regulation ........... 15 
Introduction ............................................................................................................. 16 
Materials and Methods ............................................................................................ 19 
Findings................................................................................................................... 26 
Body Weight ....................................................................................................... 26 
Intake................................................................................................................... 26 
Plasma Analyses ................................................................................................. 27 
Housekeeper Selection ........................................................................................ 27 
Gene Expression ................................................................................................. 27 
Discussion ............................................................................................................... 40 
Intake................................................................................................................... 40 
Plasma ................................................................................................................. 41 
Gene expression .................................................................................................. 42 
Cholecystokinin .................................................................................................. 43 
Corticotrophin Releasing Hormone .................................................................... 44 
Growth Hormone ................................................................................................ 45 
Receptor Activity Modifying Protein 3 .............................................................. 46 
Tumor Necrosis Factor ....................................................................................... 47 
Thyrotropin Releasing Hormone ........................................................................ 48 





Appendices .................................................................................................................. 76 
Appendix A. List of genes on RT
2
 PCR array ........................................................ 76 
Appendix B. Results of RT
2
 PCR array .................................................................. 81 
 






List of Tables 
Table 1. Primers used for pooled and individual verification RT-PCR analyses. ...... 55 
Table 2. Average body weight of rats following 24 hour sugar access ...................... 56 
Table 3. Mean chow and sugar intake following 24 hour access to sugar solutions .. 57 
Table 4. Results of plasma analyses ........................................................................... 58 
Table 5. Cycle threshold (Ct) of housekeepers ........................................................... 59 
Table 6. List of significant fold changes ..................................................................... 60 
Table 7. Summary of analysis used to determine the effect of sugar solution access on 
hypothalamic ADIPOQ. .............................................................................................. 61 
Table 8. Summary of analyses used to determine the effect of sugar solution access 
on hypothalamic ADRA2b expression ....................................................................... 62 
Table 9. Summary of the three analyses used to determine the effect of sugar solution 
access on hypothalamic AGRP. .................................................................................. 63 
Table 10. Summary of analysis used to determine the effect of sugar solution access 
on hypothalamic APOA4. ........................................................................................... 64 
Table 11. Summary of the three analyses used to determine the effect of sugar 
solution access on hypothalamic CCK. ...................................................................... 65 
Table 12. Summary of analysis used to determine the effect of sugar solution access 
on hypothalamic CLPS. .............................................................................................. 66 
Table 13. Summary of analyses used to determine the effect of sugar solution access 
on hypothalamic CRH................................................................................................. 67 
Table 14. Summary of the three analyses used to determine the effect of sugar 
solution access on hypothalamic DRD1a. .................................................................. 68 
Table 15. Summary of the three analyses used to determine the effect of sugar 
solution access on hypothalamic GH1. ....................................................................... 69 
Table 16. Summary of analyses used to determine the effect of sugar solution access 
on hypothalamic IAPP. ............................................................................................... 70 
Table 17. Summary of the three analyses used to determine the effect of sugar 




Table 18. Summary of the three analyses used to determine the effect of sugar 
solution access on hypothalamic RAMP3. ................................................................. 72 
Table 19. Summary of analyses used to determine the effect of sugar solution access 
on hypothalamic TNF-α. ............................................................................................. 73 
Table 20. Summary of analyses used to determine the effect of sugar solution access 
on hypothalamic TRH. ................................................................................................ 74 
Table 21. Summary of analyses used to determine the effect of sugar solution access 





List of Figures 
Figure 1. Relationship between fructose intake and prevalence of overweight and 
obesity. ........................................................................................................................ 52 
Figure 2. Metabolism of glucose and fructose ............................................................ 53 





List of Abbreviations 
ACTH ............................................................................... Adrenocorticotropic hormone 
ADIPOQ ...................................................................................................... Adiponectin 
ADRA2b ...................................................................... Adrenergic, alpha-2B-, receptor 
ADX ................................................................................................... Adrenalectomized 
AGRP .......................................................................................... Agouti-related peptide 
ANOVA .......................................................................................... Analysis of variance 
AP ............................................................................................................ Area postrema 
APOA4 ........................................................................................... Apolipoprotein A-IV 
ARC ....................................................................................................... Arcuate nucleus 
BP ......................................................................................................................Base pair 
CCK ...................................................................................................... Cholecystokinin 
Cdna ............................................................................................. Complementary DNA 
CHO ........................................................................................................... Carbohydrate 
CLPS ............................................................................................... Colipase, pancreatic 
CLR ............................................................................. Calcitonin receptor-like receptor 
CNS ............................................................................................ Central nervous system 
CRH/CRF .......................................................... Corticotropin-releasing hormone/factor 
CSF ................................................................................................. Cerebral spinal fluid 
Ct ........................................................................................................... Threshold Cycle 
DRD1a ..................................................................................... Dopamine receptor D1A 
GAPDH ..................................................... Glyceraldehyde 3-phosphate dehydrogenase  




GHS-R.............................................................. Growth hormone secretagogue receptor 
GPCR ................................................................................... G protein-coupled receptor 
HFCS........................................................................................ High fructose corn syrup 
IAPP ......................................................................... Islet amyloid polypeptide, Amylin 
Il1a .................................................................................................... Interleukin 1 alpha 
Il6 ................................................................................................................ Interleukin 6 
INS2 .................................................................................................................. Insulin 2 
IV .................................................................................................................. Intravenous  
KO ................................................................................................................... Knock out 
LDHA ..................................................................................... Lactate dehydrogenase A  
MCH ............................................................................ Melanin-concentrating hormone  
mRNA ..................................................................................Messenger ribonucleic acid 
MSH ........................................................................... Melanocyte-stimulating hormone 
NAC ................................................................................................. Nucleus accumbens 
NMU ........................................................................................................ Neuromedin U 
NPY........................................................................................................ Neuropeptide Y 
NTRK1 ........................................................... Neurotrophic tyrosine kinase, receptor, 1 
NTS ......................................................................................... Nucleus tractus solitarius 
PCR ....................................................................................... Polymerase chain reaction 
POMC .......................................................................................... Pro-opiomelanocortin 
PPG ........................................................................................................ Preproglucagon 
PVN.............................................................................................Periventricular nucleus 




RAMP3 ............................................................... Receptor activity modifying protein 3 
RPLP1 ................................................................................ Ribosomal protein, large, P1  
RNA ......................................................................................................Ribonucleic acid 
RT-PCR................................................................. Real time polymerase chain reaction 
Ta ................................................................................................ Annealing temperature 
TaOpt ...........................................................................Optimum annealing temperature 
TCA.................................................................................................... Tricarboxylic acid 
TG ................................................................................................................ Triglyceride 
TNF .............................................................................................. Tumor necrosis factor 
TRH/TRF ........................................................... Thyrotropin- releasing hormone/factor 











Despite years of research, and millions of dollars spent every year in 
prevention and treatment, obesity has become the nation‟s most preventable health 
problem (1, 2). The current obesity epidemic is not attributable to any one factor, and 
is not restricted by race, nationality, age or gender (3). Despite its prevalence, there is 
no known cure for this disease.  Several hypotheses about how obesity develops have 
been proposed that help guide research efforts.   
One such hypothesis is that dietary patterns of Americans have significantly 
shifted over the past fifty years by including unprecedented amounts of refined sugar 
(4).  Others have added that not all sugars are the same, and that fructose in particular 
accounts for much of the increase in sugar intake in the American diet (5, 6). From 
1970 to 1990, consumption of high fructose corn syrup (HFCS) increased more than 
1000% and currently accounts for 40% of all added caloric sweeteners (7, 8). 
Evidence that fructose is capable of promoting excessive weight gain has been 
reported in animal models and in humans. Figure 1 depicts the trends of overweight 
and obesity with the increase in fructose consumption in the US over the years. Rats 
maintained on a diet rich in HFCS for 6 or 7 months show abnormal weight gain, 
increased circulating triglycerides (TG) and augmented fat deposition (9). This 
hypothesis is not without its critics.  Several groups have reported that when tested 
side-by-side, fructose is no more or less effective in promoting excess weight gain 
(10, 11).  
It has long been established that the hypothalamus, particularly the arcuate 




examined the role of peripheral hunger and satiety messages. However in the past 15 
years exploration of the connection of the CNS to energy homeostasis has accelerated  
(13). This increase is due to increases in scientific technology including genetic 
assays as well as improvements in the study of neuroscience. In the past, ablation 
studies were the fundamental method for understanding how changes in the brain 
affect energy balance. In fact, these ablation studies are how it was originally 
established the hypothalamus is so important for appetite regulation (14).  
For the purpose of this review, literature pertaining to appetite regulatory 
genes of the hypothalamus, particularly those impacted by sugar consumption, will be 
considered. Of course there are probably hundreds of genes in the hypothalamus that 
relate to energy balance in one form or another. Therefore, genes included in this 
review were selected based upon recommendations from the manufacturer of an 
obesity related PCR array that has been used in our laboratory (SABioscience, 
Frederick, MD). The PCR system used for this analysis was a rat obesity RT² 
Profiler™ PCR Array (PARN-017A). A PCR array is a multi-well plate that has been 
pre-loaded with specified primer pairs, in this case primers for genes relating to 
obesity. RNA and PCR reagents are added to the plate and using a thermal cycler, 
quantitative changes in gene expression are measured. The benefit of this system is it 
allows for analysis of multiple genes in a single experiment in a very short time. For 
the purpose of this study, gene expression in hypothalamic tissue of rats given 24 
hour access to either glucose, sucrose, HFCS, or fructose was examined. From these 




„significant‟ and interesting changes in gene expression were selected for inclusion in 
this review.  
Amylin 
 Amylin, also known as Islet Amyloid Polypeptide (IAPP), is a 37 amino acid 
peptide hormone. Amylin reduces eating via meal size effect by promoting meal 
ending satiation. In the periphery it has been observed that amylin reduces gastric 
acid secretion, slows gastric emptying, and reduces pancreatic glucagon secretion 
(15). Pancreatic β-cells are the major source of circulating amylin and it is generally 
believed that the role of amylin in appetite regulation is as a result of secretion from 
β-cells (16).  
Amylin acts centrally via action in the area postrema (AP), which is rich in 
amylin receptors. The presence of amylin synthesized centrally is still highly debated. 
According to Lutz (2011), there is currently no evidence for central amylin synthesis  
(17). One possible reason that amylin synthesis has not been identified centrally may 
be in part due to the fact that most studies thus far have focused on male rats.  
Dobolyi and colleagues have reported that IAPP was upregulated in the preoptic area 
of the hypothalamus in the early postpartum period. Utilizing micro array technology, 
RT-PCR and in situ hybridization for verification, amylin expression was found to be 
significantly increased in dams and mothers whose pups were removed immediately 
after delivery. These findings suggest that in female rats, central amylin synthesis 





Agouti Related Peptide 
Agouti-related protein (AGRP) is a 132 amino acid obesogenic peptide 
produced in the ventromedial portion of the arcuate nucleus in the hypothalamus. 
AGRP and neuropeptide Y (NPY) are co-expressed and both are produced in 
AGRP/NPY neurons. AGRP is one of the most potent and long-lasting of appetite 
stimulators.  
Release of AGRP and NPY from AGRP/NPY neurons is inhibited by insulin. 
By inactivating the insulin receptor on AGRP neurons, Konner and colleagues found 
that insulin failed to regulate hepatic glucose production (19). This result 
demonstrates the importance of AGRP in insulin-induced suppression of hepatic 
glucose production. These findings suggest that AGRP may be a new target for type 2 
diabetes therapies. 
Given that AGRP and NPY are involved in insulin regulation, it is not 
surprising that they are activated by sugar intake.  Sucrose intake causes direct 
changes in NPY and AGRP expression in the ARC. Following a sucrose preload, 
AGRP and NPY mRNA expression was suppressed for the first 10 min following 
preload. During this interval there was also in increase in plasma and CSF glucose. In 
the subsequent interval (30-60 min) AGRP and NPY mRNA expression then 
increased (20).  
Sucrose preloads increased intake in the subsequent meal as compared to a 
starch preload. Leibowitz and colleagues have suggested that sucrose causes 
increased intake and hunger following intake due to increased expression of 




AGRP‟s orexegenic mechanisms are directed toward increased consumption of CHO 
where as other orexogenic peptides may act to increase intake of fats (20). 
 
Cholecystokinin 
Cholecystokinin (CCK) is an anorexogenic peptide that is expressed in both 
the small intestine and the brain. CCK was discovered in 1928 in a study examining 
the ability of intestinal extracts to stimulate gallbladder contraction in dogs. However, 
CCK was not purified and sequenced until 1966 by Jorpes and Mutt (22). CCK comes 
in many forms, denoted by size. For example, CCK-33, which was the first to be 
discovered, is a 33-amino acid peptide. The most common CCK form is CCK-8, 
which is an 8 amino acid peptide. All forms of CCK are derived from the same CCK 
gene by post translational or extracellular processing. Expression of CCK results in 
short duration reduction of meal size (23). 
Despite much of the literature surrounding CCK being focused on its 
expression in the gut, CCK is one of the must abundantly expressed peptides in the 
brain (24). In the brain, CCK is expressed in the cerebellum, cortex, midbrain, 
hypothalamus and hippocampus (25). 
Woods et al have theorized that CCK has two roles in satiation. First,  CCK 
signals a reduction in meal size and second, CCK acts as a mediator of the satiation 
process (13). CCK is a mediator of the satiation process via many mechanisms 
including increasing hypothalamic permeability to leptin (26). Leptin is a signal for 
overall body adiposity status and CCK is a gatekeeper for this message entering the 




It has been suggested that obesity, as a result of leptin resistance, may be due 
to impaired transport of leptin from the blood into the CNS (26). Rats that lack the 
CCK1 receptor are resistant to peripheral leptin but not leptin directly infused into the 
brain. To explore the connection between CCK and leptin, Cano et al administered 
leptin in the periphery to animals that had been given a CCK-1 receptor antagonist. 
They found that although leptin gradually decreased in the plasma, it simultaneous 
increased in concentration in the CSF (26). This finding suggests that leptin builds up 
in the periphery when CCK is blocked. Thus CCK increases leptin permeability into 
the CNS. 
Insulin, in its role as another adiposity signal, is also linked to CCK 
expression. Lo (2011) using CCK-KO mice, found that when maintained on a low-fat 
diet animals had a reduced acute insulin response to glucose (27). However, when 
maintained on a high fat diet, CCK-KO mice developed glucose intolerance. The 
importance of this finding is it shows that CCK is required for regulating both insulin 
secretion and glucose tolerance in mice on a high fat diet.  
 Hisadome and colleagues found that an important role of CCK is to regulate 
neuronal circuitry (28). The aim of their study was to investigate the circuitry which 
links CCK to nucleus tractus solitarius- preproglucagon (NTS-PPG) neurons. PPG 
neurons express Glucagon-like peptide-1 which acts to modulate gastric emptying, 
glucose homeostasis, and appetite control. The researchers found that CCK does 
modulate the activity of PPG neurons however does so indirectly by acting through 




Corticotrophin Releasing Hormone 
Corticotropin-releasing hormone (CRH), also known as Corticotropin-
releasing factor (CRF) is a 41-amino acid anorectic peptide. CRF was first identified 
by Vale in 1981 (29). CRH is secreted by neurosecretory cells of the parvocellular 
region of the periventricular nucleus (PVN) of the hypothalamus and carried via the 
portal system to the anterior lobe of the pituitary where it promotes ACTH production 
(30). There are few studies relating CRH to diet and circulating nutrients. CRH has 
been found to have little response to increases in fat intake (21). Widmaier found that 
when glucose was removed from an extracted section of rat hypothalamus, there was 
in increase in CRF production that could be reversed by adding back glucose (31). 
This increase in CRF as a response to a lack of glucose may be to stimulate 
glucocorticoid release.  Jang and colleagues found that in rats lacking glucocorticoids 
(via adrenalectomy), leptin administration rapidly increased CRH secretion (and 
decreased NPY secretion) (32). 
Given the connection between CRF and glucose, it is no surprise that there is 
also a connection between CRH and insulin. When leptin is centrally injected, CRH 
mRNA expression in the PVN is increased. However, the opposite effect is observed 
when glucocorticoids are administered (32). This finding suggests that interactions 
between leptin and glucocorticoids regulate CRH. 
The effect of sucrose on CRF expression has also been evaluated. Daily 
limited access to a sucrose sweetened drink resulted in decreased CRH mRNA 
expression (33). When adrenalectomized (ADX) rats were allowed to consume 




have normal CRF levels throughout the brain (34). This finding suggests that CRF 




Dopamine is catecholamine (biogenic amine) synthesized from tyrosine. Both 
are derived. All three catecholamines in this pathway (norepinephrine, epinephrine, 
and dopamine) function as neurotransmitters. Dopamine is released from the nucleus 
accumbens and the dorsal striatum in response to intake of palatable foods such as 
sugar (35). The hypothalamus has also been cited as a site of dopamine action in 
response to sucrose intake (36-39). Though dopamine has many actions in the brain, 
actions relating to intake will be the focus of this review. 
Dopamine is probably not directly involved in huger and satiety mechanisms 
but rather influences food intake via reward mechanisms. When palatable foods are 
consumed, reward pathways, including the nigrostriatal dopaminergic pathway, are 
activated (40). Foods that are high in sugar and fat are known to activate the reward 
system and promote eating and prompt conditioning (41). Dopamine antagonists will 
attenuate this response and supress intake of sweets in rats (40, 42-44).  
Overeating obesogenic diets blunts the dopamine signalling pathway. 
Increased consumption of sugars compensates for this blunted reward pathway (43). 
Pritchett and colleagues induced obesity in rats with a high fat/high CHO diet. Rats 




consumed less sugar solution then obese and thus obese animals had reduced 
dopamine receptor signalling (43).  
 Genetic differences in the dopamine gene have been shown to result in 
differences in acquisition of sugar preference. Dym et al. found that genetic 
differences between standard breeds of mice result in differences in the expression of 
the learned sucrose preference phenotype (45). Dym has attributed this to be a result 
of polymorphisms of taste receptors. Other researchers have found that newly 
discovered taste receptors in the gut may trigger dopamine responses upon exposure 
to sucrose (46). Similar reports of the impact of sugar on dopamine release have been 
reported by both Hoebel and Smith. Hoebel postulated that there may a connection 
with excessive sucrose intake and changes in the dopaminergic pathway in the 
hypothalamus (36). Smith and colleagues also reported similar conclusions- 




Growth hormone (GH) is a 191 amino acid long hormone. GH is released by 
the lateral wings of the anterior pituitary gland and regulated by neurosecretory nuclei 
of the hypothalamus.  The GH1 gene encodes the protein somatotropin. GH is 
thought to be an anorexogenic peptide that not only contributes to the regulation of 
energy expenditure but also growth. However, there is limited literature surrounding 
the effects of Growth Hormone (GH) on the regulation of energy balance and intake. 
Much of the literature surrounding GH is centered around the effects of ghrelin on 




stimulate the release of GH via binding to growth hormone secretagogue receptor 
(GHS-R) (47, 48). 
Several reports of the effects of GH on fasted or food limited animals have 
been published. During fasting and anorexia, insulin is suppressed and GH is 
elevated. The reason behind this elevation is thought to be due to GH antagonizing 
the actions of insulin so as to promote lipolysis and lipid oxidation (49). Gahete and 
colleagues examined this connection using female adult onset, isolated GH-deficient 
mice. These animals showed increased fat depot weight as compared to controls. This 
suggests that the importance of GH during fasting is more for the support of fat 
mobilization for gluconeogenesis and muscle function rather than for the maintenance 
of glucose levels (50). 
Strauch and colleagues examined the effects of fructose on plasma GH levels 
in humans (51). They reported that in humans fructose, when administered IV at a 
dosage between 0.3 and 0.5 g/kg, is a potent stimulator of GH secretion. These results 
were in contrast to previous reports surrounding the effects of glucose on GH which 
suggested that glucose suppressed GH secretion.   
 
Neuropeptide Y 
Neuropeptide Y (NPY) is a 36 amino acid, obesogenic peptide that also acts 
as a neurotransmitter in the arcuate nucleus of hypothalamus. NPY is co-localized on 
neurons with AGRP (Agouti-related peptide). NPY has a dramatic effect on 




levels of both insulin and leptin (53-55). When insulin and leptin levels in the plasma 
are low, NPY/AGRP expression is increased (32, 56).  
There has also been extensive work done to evaluate the effects of 
carbohydrates on NPY expression. There is a strong NPY expression peak at the start 
of the natural feeding period that is thought to support the utilization of carbohydrate 
(21).  In 1988, Rowland reported that animals given injections of NPY into the PVN 
there is a robust increase in feeding. This affect is then attenuated when an IV dose of 
glucose is given. The attenuation however does not occur when a dose of fructose is 
administered (57). This finding demonstrates that these two monosaccharide‟s have 
different effects on the regulation of this potent stimulator of intake. It is also 
significant because it shows that fructose does not have the same ability to inhibit 
NPY-induced feeding as does glucose.  
 
Receptor Activity Modifying Protein 3 
Receptor activity modifying protein 3 (RAMP3) is a G protein-coupled 
receptor (GPCR) accessory protein in the family of RAMP. RAMP proteins were 
originally identified in association with calcitonin receptor-like receptors (CLR). One 
function of RAMP3 is to interact with the calcitonin receptor to produce amylin 
receptor complexes. Once formed, these complexes allow binding of amylin to the 
receptor. Another function of RAMP3 is to complex with calcitonin receptor-like 
receptor (CLR) to form adrenomedullin receptors (15, 58). Because the RAMP family 
plays such an important role in the transport and modulation of GPCRs, there have 




for modulating GPCRs for the sake of disease treatment. Though much is known 
about the function of this protein, little has been reported on the specific impact of 
RAMP3 in the control of intake and energy balance. 
To examine the life-long impact of RAMP3 deletions and the overlapping 
effects of RAMP proteins, Dackor and colleagues developed mouse strains with 
targeted RAMP deletions. Although mice with RAMP2 deletions had severely 
impaired fertility, RAMP3 deletions did not show any phenotypic differences from 
control until later in life. In late life, animals lacking the RAMP3 gene had difficulty 
maintaining body weight however the researchers note that the mechanism behind 
this is not yet understood (59).  
 
Tumor Necrosis Factor 
Tumor Necrosis Factor-α (TNF-α) is a 212 amino acid inflammatory cytokine 
found in the hypothalamus. TNF plays in active role in inflammation and obesity and 
is involved in lipid metabolism regulation, adipocyte differentiation, and insulin 
sensitivity (60). TNF has been shown to interact with well-known satiety signals such 
as leptin. Huypens has proposed a model for TNF that suggests the gene has a role in 
the regulation of the inverse relationship between ADIPOQ and leptin (61).  
 In a study by Wang and colleagues rats were fed a high fat diet to induce 
obesity then were switched to a chow diet. Gene expression experiments revealed that 
many inflammatory cytokines, including TNF, were elevated following induction of 
obesity. After the switch to a regular chow diet however, the upregulation of these 




inflammatory response that results from obesity (62). This is an important finding that 
may impact the way obesity therapies are designed.  
 
Thyrotropin Releasing Hormone 
 
Thyrotropin- releasing hormone (TRH), also called Thyrotropin- releasing 
factor (TRF), is a 242 amino acid hormone produced in the PVN of the hypothalamus 
that functions to stimulate the release of thyroid stimulating hormone and prolactin 
from the anterior pituitary. TRH is an anorectic hormone.  
 The mechanism of TRH action on appetite regulation is not yet fully 
understood (63).  Zhang and van den Pol found that in addition to reducing intake, 
body weight and sleep, central injections of TRH also inhibited melanin-
concentrating hormone (MCH) neurons. MCH neurons increase food intake (64). 
This finding may suggest that the reduction of food intake following TRH 
administration may be through TRH acting on MCH neurons (63). 
Leptin has been found to have direct and indirect (through activating POMC 
neurons that in turn release αMSH to stimulate TRH) effects on stimulation of TRH 
synthesis (65). NPY also acts on TRH as an inhibitor through activation of NPY 




















Despite years of research, and millions of dollars spent every year in 
prevention and treatment, obesity has become the nation‟s most preventable health 
problem (1, 2). The current obesity epidemic is not attributable to any one factor, and 
is not restricted by race, nationality, age or gender (3). Despite its prevalence, there is 
no known cure for this disease.  Several hypotheses about how obesity develops have 
been proposed that help guide research efforts.   
One such hypothesis is that dietary patterns of Americans have significantly 
shifted over the past fifty years by including unprecedented amounts of refined sugar 
(4). Others have added that not all sugars are the same, and that fructose in particular 
accounts for much of the increase in sugar intake in the American diet (5, 6).  From 
1970 to 1990, consumption of high fructose corn syrup (HFCS) increased more than 
1000% and currently accounts for 40% of all added caloric sweeteners (7, 8). 
Evidence that fructose is capable of promoting excessive weight gain has been 
reported in animal models and in humans. Figure 1 depicts the trends of overweight 
and obesity with the increase in fructose consumption in the US over the years. Rats 
maintained on a diet rich in HFCS for 6 or 7 months show abnormal weight gain, 
increased circulating TG and augmented fat deposition (9). This hypothesis is not 
without its critics. Several groups have reported that when tested side-by-side, 
fructose is no more or less effective in promoting excess weight gain (10, 11).  
However, the rise in circulating TG can be explained by the metabolism of 
fructose. Fructose is metabolized differently than glucose, the more common 




when glucose enters the cell there are multiple control points that regulate the 
conversion of glucose to fat (triglycerides).  However these control points do not exist 
in the metabolism of fructose and thus fructose is readily metabolized into 
triglycerides.  
In the laboratory, sugar-induced obesity can be studied by giving rats access 
to any of a wide variety of sugar solutions, from which they will consume 
approximately 60% of their total daily caloric intake from the solution, despite 
differences in concentration and sweetness (12-14).  Long term access to sucrose, 
glucose, and fructose promote increased weight gain and a shift in body composition 
favoring increased fat deposition (9).  Despite the extensive behavioral examinations 
of the rat‟s avidity for sugar solutions, relatively little work has been focused on the 
impact of sugar intake on the hepatic and central mechanisms controlling intake.  
Exceptions to this characterization are the work of Erlanson-Albertsson and 
colleagues, who have demonstrated that fructose can upregulate fatty acid amide 
hydrolase, an enzyme involved in the degradation of hypothalamic endocannabinoids, 
as well as other enzymes involved in the synthesis of endocannabinoids (67).  Hoebel 
and colleagues have reported on the pronounced effects of sugar solutions on the 
release of dopamine in the nucleus accumbens (NAc), the brain‟s so-called “reward 
center” (68, 69). In addition to dopamine release, this group has demonstrated that 
sugar consumption can alter receptor gene expression in reward areas of the brain.  
We have more recently added to this literature by reporting that fructose 




dehydrogenase -1, an enzyme that regulates intracellular glucocorticoids in adipose 
tissue (70, 71).  
 The purpose of the present experiment was to directly compare the efficacy 
of fructose with high fructose corn syrup. To do this, we used a PCR array system 
which evaluates 86 different obesity related genes on hypothalamic tissue. Once 
genes with significant changes were identified, we verified the array findings using 
traditional RT-PCR using primers that were designed in house (pooled verification). 
To further verify these findings gene expression in individual animals was evaluated 
with these primers as well (individual verification). It was our intention to establish a 
sound collection of evidence from these three approaches to determine the effects of 





Materials and Methods 
Animals  
Adult male Sprague-Dawley (CD strain) rats (Charles River Laboratories, 
Wilmington, MA) with a mean weight of approximately 300 grams were used. Upon 
arrival, all animals were individually housed and maintained on a 12h light/dark cycle 
with a room temperature of 22° C ± 1° C. During the 1 wk acclimation period the rats 
were given free access to the control diet and water. Animals were weighed and 24h 
food intake and sugar solution intake (when appropriate) were measured daily at 
0900h throughout the experiment.  
All rats were killed by slow replacement of air in a specialized chamber with 
pure CO2 followed by rapid decapitation and exsanguination. This method has been 
approved for use by the Panel on Euthanasia of the American Veterinary Medical 
Association as well as the UM IACUC. All procedures described herein are in 
compliance with the University of Maryland‟s IACUC guidelines.  
 
Animal Diets  
The control diet used in these experiments is based upon one previously used 
in an experiment that manipulated quality and quantity of fat in diet-induced obesity 
studies with rats (72). The diet is a nutritionally complete low fat diet [Rodent diet 
7012] prepared by Harlan Teklad (Bethlehem, PA) and provides 3.41 metabolizable 
kcal/g of diet. Per gram of chow, 2.14 kcal were derived from carbohydrate, 0.79 kcal 
was derived from protein, and 0.51 kcal was derived from fat.  All animals were 




Study Design  
Rats (N=44) were randomly assigned to one of five weight-matched groups 
(n=8, control n=12) after an initial 1 wk acclimation period during which they had ad 
lib access to food and water. The rats assigned to the first group had ad libitum 
control diet (Harlan rodent diet 7012) only, and served as the control group. Rats 
assigned to the second group had ad libitum access to the control diet and free access 
to a 16% weight/volume fructose (Tate & Lyle, Decatur IL) solution. Rats assigned to 
the third group had ad libitum access to the control diet plus free access to a 16% 
glucose weight/volume (Sigma Aldrich, St Louis MO) solution. Rats assigned to the 
fourth group had ad libitum access to the control diet and free access to 16% high 
fructose corn syrup (HFCS) weight/volume (Tate & Lyle, Decatur IL), Finally, rats 
assigned to the fifth group had ad libitum access to the control diet and free access to 
a 16% weight/volume sucrose (Domino Foods, Baltimore MD) solution. All sugar 
solutions were prepared 24h in advance and stored at 4°C. The rats were maintained 
on their respective diets for 24h and then sacrificed. At the time of sacrifice, livers 
(lobus lateralis sinister) were dissected and flash frozen for storage at -80°C. Brains 
were removed and flash frozen at -80°C for subsequent dissection. Frozen brains 
were sectioned using an IEC Minot Custom Microtome (Damon/IEC Division) and 8-
9, 80-100 micron-thick consecutive tissue slices were sectioned from the 
hypothalamic region starting at the interaural line +6.44 mm. Figure 3 shows the 





Plasma insulin concentrations were measured by ELISA (LINCOplex; LINCO 
Research). Plasma glucose concentrations were measured enzymatically (Smith-Kline 
Beecham Laboratories). All reactions were run in duplicate. 
 The Dimension clinical chemistry system Flex reagent cartridge (Siemens 
Healthcare Diagnostics, Newark, DE) was used with a Dade Behring Dimension 
Xpand automated system to quantify plasma triglyceride levels. The assay is based on 
an enzymatic procedure using a combination of lipoprotein lipase, glycerol kinase, 
glycerol-3-phosphate-oxidase, and peroxidase. Changes in absorbance (510, 700 nm) 
resulting from the formation of quinoneimine from hydrogen peroxide reflect the total 
amount of glycerol and its precursors. All reactions were run in duplicate. 
 
RNA Extraction 
Total RNA was extracted from each hypothalamic sample according to 
RNeasy Mini and RNeasy Lipid (QIAGEN) kit directions. The samples were purified 
with DNA-free (Ambion) and analyzed spectrophotometrically (Nanodrop) to 
determine concentration and check for quality. cDNA template was created for each 




cDNA was made using the SABiosciences RT² First Strand Kit. A genomic 




group (equal quantity from each animal) that was then mixed with 2.0 ul of 5X qDNA 
elimination buffer and RNase-free H20 to a final volume of 10 ul. Contents were 
mixed gently, incubated at 42˚C for 5 minutes and chilled on ice. An RT cocktail was 
then prepared, containing 5X RT Buffer 3, Primer & External Control Mix, RT 
Enzyme Mix 3, and RNase free H20. 10 ul of the RT cocktail was added to each 
genomic DNA elimination mixture, mixed well, and incubated at 42˚C for exactly 15 
min and then immediately stopped by heating at 95˚C for 5 min. 91 ul of ddH20 was 
added to each 20 uL of cDNA synthesis reaction and the solution was mixed well and 
stored at -20˚C. 34 uL of each sample from each experimental group was taken and 
pooled to create the master stock of cDNA used for the arrays and pooled verification 
assay. Hypothalamic cDNA templates from each experimental group were pooled by 
diet.   
 
Measurement of Gene Expression 
Changes in gene expression were measured in three ways, RT
2
 PCR array, 
pooled verification, and an individual verification. Hypothalamic cDNA from each 
group was pooled and served as the genetic material for both the array and the pooled 
verification assay. After completing the array, „significant‟ results were identified and 
those that were „significant‟ and also of interest to the study of sugars effects on 
hypothalamic appetite regulation were selected for follow up verification assays. 
Primers were designed for each of these genes and standard RT-PCR experiments 
were run using pooled hypothalamic cDNA (pooled verification). If quality results 




In the individual verification assay, hypothalamic cDNA from individual rats (n=4 
per group) were analyzed using aforementioned primers and standard RT-PCR, 
results were then averaged for each group. Selection of the four animals included in 
the individual verification was based on those with the highest quality cDNA as 




 Profiler™ PCR Array 
Ten Rat Obesity RT² Profiler™ PCR Arrays (PARN-017A) were purchased 
from SABiosciences (Frederick, MD). Each array profiled the expression of 84 genes 
related to obesity, including genes that code for orexigenic peptides, hormones, and 
receptors, anorectic peptides, hormones, and receptors, and central and peripheral 
signaling molecules related to energy expenditure. Arrays also include 5 
housekeepers and 7 controls.  See appendix A for the complete list of genes included 
in the array.  
Diluted First Strand cDNA was added to the 2X SABiosciences RT
2
 qPCR 
Master Mix and aliquoted into each of 96-wells of the obesity arrays. Arrays were run 
according to the SABiosciences protocol: 95˚C for 10 min, and 40 cycles at 95˚C, 15 
s; and 60˚C, 1 min. Results were analyzed using the SABioscience‟s online RT² 
Profiler™ PCR Array Data Analysis software. Fold change was calculated as 2^(-
ddCt) using SABioscience‟s online PCR array analysis software. Fold change of 0.5 





Custom Primer Design and Optimization  
Using the array data as a guide, primers were designed for the majority of the 
genes that were significantly upregulated or downregulated in the array to be used in 
conventional RT PCR reactions. These included: ADIPOQ, ADRA2b, AGRP, 
APOA4, CCK, CLPS, CRH, DRD1a, GH1, IAPP, NPY, RAMP3, TNF, TRH, and 
UCN. Additionally, β actin, Ribosomal protein, large, P1 (RPLP1), Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), and Lactate dehydrogenase A (LDHA) were 
evaluated as housekeepers. Upon initial evaluation, LDHA was eliminated as an 
option for housekeeper because the average Ct was much higher than with the other 
housekeeper options. With the exception of TNF, primers were designed using 
Beacon Designer 7 software default parameters (PREMIER Biosoft, Palo Alto, CA). 
TNF was sourced from Yang et al, 2011(73).  
Primers were evaluated using the CFX96 (BioRad) protocol, using a gradient 
that was centered around predicted optimum annealing temperature (TaOpt). The 
protocol for primer verification PCR is as follows: 95°C, 3 min, and 40 cycles at 
95°C for 10 sec, at a gradient of temperatures for 30 sec with subsequent melt curve  
of 65°- 95°C at increments of 0.5°C for 5 sec.  Empirically optimal Ta was 
determined for each primer set from these results. Housekeepers were selected based 
on the least variation in cycles between groups. See Table 1 for primer sequences and 





Pooled Verification Assay 
Following determination of TaOpt from the primer verification assay, 
successful primers were evaluated on pooled group cDNA (glucose, sucrose, HFCS, 
fructose, and control).  RPLP1 served as the housekeeper for each gene of interest. 
All reactions were carried out in duplicate.  
Fold change was calculated as 2^(-ddCt). Fold change of 0.5 or less or of 1.5 
or greater were considered „significant.‟ 
 
Individual Verification Assay 
cDNA was synthesized from individual animals with highest quality RNA, 
four animals per group, as previously described. Primers that were successful on the 
group level were evaluated on 20 individual rat cDNA (4 animals from each group). 
RPLP1 served as the housekeeper for each gene of interest. All reactions were carried 
out in duplicate. 
Fold change was calculated as 2^(-ddCt). Fold change of 0.5 or less or of 1.5 







Twenty-four hour access to any of the four sugar solutions used failed to 
promote significant differences in body weight (p<0.05). Refer to body weight data 




All four treatment groups consumed significantly less chow (p<0.001) than 
did controls during the 24h access period. HFCS fed animals consumed significantly 
less chow than either fructose or glucose fed groups (p<0.05) Refer to intake data 
presented in Table 3. 
 
Sugar 
HFCS fed animals consumed significantly greater amounts of sugar compared 
to the group fed glucose (p<0.05). No other differences among groups were found.  
Refer to intake data presented in Table 3. 
 
Total Intake 
Control animals consumed significantly fewer total calories than the groups 
given access to sugar solutions (p<0.05). No other differences were observed.  Refer 





Fructose consumption caused significant upregulation in circulating 
triglycerides (p<0.05). No differences among the five groups in plasma insulin or 
plasma glucose were found. Refer to plasma data presented in Table 4. 
 
Housekeeper Selection 
It has long been recognized that the selection of a housekeeper gene should be 
determined by that gene‟s resistance to treatment effects.  We examined several 
standard housekeepers and found that all but one was significantly affected by sugar 
solution consumption. RPLP1 was the only primer analyzed whose cycle threshold 
did not vary across treatments (Duncan‟s new multiple range test p<0.05).  Refer to 
housekeeper selection data presented in Table 5. 
For these reasons, β-Actin, and GAPDH were excluded as options for 
housekeeper, leaving RPLP1 to be used as reference gene for all subsequent analyses. 
 
Gene Expression  
Inclusion and Exclusion Criteria 
In order to expedite the interpretation of the many possible outcomes of the 
array analysis, we sorted the data into two categories: „significant‟ and „not 
significant‟ Fold change of 0.5 or less or of 1.5 or greater were considered 
„significant.‟ Fold change was calculated as 2^(-ddCt) using SABiosciences online 




assays. Refer to Appendix B for complete results of PCR array analyses. Refer to 
Table 6 for a list of those genes that were „significant.‟ 
Additionally, data were not included for subsequent analyses if mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples were too low for consideration. Subsequent 
individual verification PCR was not performed 
 
Adiponectin (ADIPOQ) 
ANOVA performed on PCR array analyses did not reveal any significant 
differences among treatments (ANOVA F=4.23, df= 4, P=0.0729). Duncan‟s new 
multiple range test however revealed a significant upregulation of ADIPOQ message 
with glucose consumption (374%). In glucose fed animals ADIPOQ was significantly 
upregulated when compared to control as was sucrose and HFCS. Though 
upregulated 236%, the fructose group did not differ from the other experimental 
groups (p<0.05). Data are presented in Table 7. 
ANOVA was not applied to the pooled PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration. Because of this, 
subsequent individual verification PCR was not performed.  
 
Adrenergic 2b receptor (ADRA2b) 
Analysis of variance applied to the PCR array data revealed that access to a 




p=0.003). Post hoc analyses of group means found that ADRA2b in the hypothalamus 
was significantly downregulated by fructose by 52% and HFCS by 65% (Duncan‟s 
new multiple range test, p<0.05). The mean fold change of the glucose group was 
significantly higher than that of the sucrose group, but neither differed from control.  
Data are presented in Table 8. 
ANOVA applied to the verification assay replicated the observation that sugar 
access significantly affected ADRA2b message (ANOVA F=163.38, df=4, 
p<0.0001). Duncan‟s new multiple range tests revealed that glucose and sucrose 
significantly upregulated ADRA2b message by 1461% and 1180% respectively 
(p<0.05). The two groups were significantly different from each other and both were 
different from the remaining experimental groups. No other statistically significant 
differences were observed. Data are presented in Table 8. 
ANOVA was not applied to the individual PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration.  
 
Agouti related peptide (Agrp) 
ANOVA applied to the array data revealed that sugar access had a significant 
effect on AGRP message in the hypothalamus (ANOVA F=18.73, df=4, p=0.0033). 
HFCS promoted a 199% upregulation of AGRP message when compared to control 
(p<0.05).  No other differences were observed. Data are presented in Table 9. 
ANOVA applied to the pooled data failed to reveal any effect of sugar access 




Duncan‟s new multiple range test verified that there were no differences between 
group (p>0.05). Data are presented in Table 9. 
Similarly, ANOVA of individual verification assays revealed no significant 
effect of sugar access on AGRP message (ANOVA F=1, df=3, p=0.4659). Duncan‟s 
new multiple range test revealed that there was a 3222% upregulation in AGRP 
message with consumption of HFCS (p<0.05). Data are presented in Table 9. 
 
Apolipoprotein A-IV (APOA4) 
ANOVA applied to the PCR array data revealed that there are differences in 
APOA4 expression with consumption of different sugars (ANOVA F=18.8, df= 4, 
P=0.0032). Duncan‟s new multiple range test revealed that the only significant 
changes were the downregulation of APOA4 message (p<0.05). The greatest change 
was a downregulation of 70% that resulted from sucrose intake. Also significant was 
a 39% downregulation of APOA4 by fructose consumption. Data are presented in 
Table 10. 
ANOVA was not applied to the pooled PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration. Because of this, 
subsequent individual verification PCR was not performed.  
 
Cholecystokinin (CCK) 
Variations in sugar solutions have significant effects on the regulation of CCK 




df= 4, p<0.0001). The PCR array revealed that glucose promoted a 198% 
upregulation of CCK in the hypothalamus. HFCS and sucrose upregulated CCK 
expression by 139% and 123% respectively. By contrast, fructose promoted a 37% 
reduction in CCK expression as compared to control.  Duncan‟s new multiple range 
tests that were used to determine differences between group mean fold changes 
revealed that all groups were statistically different from one another and control 
(p<0.05). Data are presented in Table 11. 
For the most part, results from the PCR array were replicated in the pooled 
verification analyses. Glucose was markedly upregulated, 187%, and fructose was 
markedly downregulated, 60% in the pooled analyses. The Duncan‟s new multiple 
range test revealed that these differences were statistically different from each other 
(p<0.05) as well as the remaining experimental groups. No differences were observed 
between the control group and the sucrose and HFCS groups. Data are presented in 
Table 11. 
Due to variability between animals, results from the individual verification 
analyses were not significant using ANOVA (F=164.45, df= 4, p=0.0984). However, 
subsequent Duncan‟s new multiple range test confirmed the observation for the 
pooled verification that glucose caused the greatest upregulation (637%) in CCK 
message (p<0.05). Data are presented in Table 11. 
 
Colipase (CLPS)  
ANOVA applied to the PCR array data revealed that there are no differences 




P=0.7). Duncan‟s new multiple range tests further revealed that there were not 
significant changes in CLPS. Data are presented in Table 12. 
ANOVA was not applied to the pooled PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration. Because of this, 
subsequent individual verification PCR was not performed. 
 
Corticotropin Releasing Hormone (CRH) 
Results from ANOVA of PCR array data revealed that different sugars result 
in significant changes in the expression of CRH in the hypothalamus (ANOVA 
F=20.09, df=4, p=0.0028). Subsequent post hoc tests revealed HFCS induced a 51% 
downregulation in CRH expression (p<0.05). The remaining groups did not differ 
from control. Data are presented in Table 13. 
Results from the array were replicated in the pooled verification. Sugar 
consumption caused significant changes in CRH expression (ANOVA F=163.38, 
df=4, p<0.0001). Fructose was upregulated by 124% (Duncan‟s new multiple range 
test p<0.05). Also, both glucose and HFCS ingestion resulted in downregulation of 
CRH message in the hypothalamus, by 28% and 73% respectively. Sucrose did not 
significantly affect expression. The remaining groups significantly differed from 
control. Data are presented in Table 13. 
In both the array and the pooled verification, HFCS caused a significant 




Because of time and resource limitations individual verification was not 
performed for CRH.  
 
Dopamine Receptor 1a (DRD1a) 
Results from ANOVA revealed a significant effect of sugar consumption on 
expression in DRD1a using the PCR array system (ANOVA F=52.33, df=4, 
p=0.0003). Duncan‟s new multiple range test determined that both HFCS and sucrose 
caused changes in DRD1a expression that was significantly different from control 
(p<0.05). HFCS was upregulated 207% and sucrose was downregulated 30%. 
Remaining groups did not differ from control. Data are presented in Table 14. 
The subsequent pooled verification assay also revealed differences between 
experimental groups (ANOVA F=5.38, df=4, p=0.0467). Duncan‟s new multiple 
range test found that glucose and HFCS did not differ from control (p<0.05). Fructose 
caused a 415% upregulation of DRD1a message (p<0.05). Sucrose also caused a 
significant upregulation in DRD1a expression, 332% (p<0.05). Data are presented in 
Table 14. 
ANOVA was not applied to the individual PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 








Growth hormone (GH1) 
Different sugar solutions caused significant changes in expression of GH1 as 
revealed by a group effect (ANOVA F=12.96, df= 4, p=0.0075).  Using the PCR 
array system we found that glucose causes a 332% upregulation in expression of the 
GH1 gene when compared to controls (Duncan‟s new multiple range test p<0.05). No 
other significant differences were observed between groups. Data are presented in 
Table 15. 
The pooled verification analysis also revealed a significant group effect of 
sugar solutions on GH1 expression (ANOVA F=31.7, df= 4, p=0.001). Using 
Duncan‟s new multiple range test, it was again observed that glucose consumption 
results in a significant upregulation of GH1, 393% (p<0.05). Fructose fed animals 
also expressed upregulation of hypothalamic GH1 by 254%. Upregulation was also 
observed, though less robust, in the sucrose group with a 167% increase in the 
expression of GH1. Data are presented in Table 15.  
ANOVA was not applied to the individual PCR data due to fact that the mean 
thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration. Data are presented in 
Table 15. 
 
Islet amyloid polypeptide (IAPP) 
Although results from the PCR array do not reveal any differences between 
treatments for IAPP expression (ANOVA F=1.4, df= 4, p=0.3552), ANOVA of 




verification, there was a 483% upregulation of hypothalamic IAPP message induced 
by glucose consumption (Duncan‟s new multiple range test p<0.05). Fructose also 
induced upregulation of IAPP message with a mean fold change of 2.98. No other 
significant changes were observed.  Data are presented in Table 16. 
ANOVA was not applied to the pooled verification PCR data due to fact that 
the mean thresholds were higher than 36 cycles, suggesting that the existing message 
concentrations in these samples was too low for consideration. Data are presented in 
Table 16. 
 
Neuropeptide Y (NPY) 
Results from the PCR array revealed that HFCS had a significant impact on 
NPY expression (ANOVA F=24.08, df= 4, p=0.0018).  Duncan‟s New Multiple 
range tests that were used to determine differences between group means revealed 
that HFCS promoted a 227% upregulation in the expression of NPY in the 
hypothalamus when compared to controls (p<0.05).  No other significant differences 
between group means were observed. Data are presented in Table 17. 
ANOVA applied to the subsequent pooled verification analyses revealed a 
significant treatment effect (ANOVA F=36.07, df= 4, P=0.0007).  The Duncan‟s new 
multiple range tests failed to replicate the upregulation of NPY observed with the 
array analyses.  No statistically significant difference between the HFCS fed animals 
and controls was found. On the other hand, glucose fed animals had a 49% reduction 




Individual verification analyses replicated the array results (ANOVA F=16.33, 
df= 4, p<0.001).  Hypothalamic NPY in HFCS fed rats was upregulated by 352% 
compared to control. The downregulation of NPY message in glucose fed animals, as 
observed in the pooled verification analysis, failed to replicate. Data are presented in 
Table 17.  
In both the pooled verification as well as the individual verification, no 
differences were observed between sucrose and fructose fed animals. Both groups 
showed slight downregulation in the pooled verification (approximately 25% less 
then control, and in individual verification assay results showed approximately a 25% 
upregulation as compared to control. 
 
Receptor (G protein-coupled) activity modifying protein 3 (RAMP3) 
Results from the PCR array analysis revealed that sugars caused significant 
changes in the expression of RAMP3 (ANOVA F=36.03, df= 4, P=0.0007).  Results 
from Duncan‟s new multiple range tests revealed specific differences in RAMP3 
regulation by different sugar solutions. Glucose resulted in the greatest upregulation, 
(by 132% as compared to control, p<0.05). Fructose and HFCS however promoted 
downregulation in hypothalamic RAMP3 expression, by 47% and 56% respectively 
(both p<0.05). RAMP3 expression in animals consuming sucrose did not differ from 
control (p>0.05). Data are presented in Table 18. 
Results from the pooled verification analysis replicated the results from the 
PCR array. ANOVA revealed that there were significant differences between the 




the PCR array results, glucose promoted the greatest upregulation of RAMP3 
expression, by170% (p<0.05).  HFCS and fructose downregulated RAMP3 message 
by 45% and 43% respectively (both p<0.05). Sucrose led to an upregulation of 
RAMP3 expression. RAMP3 in the sucrose group was significantly higher than the 
other treatment groups as well as the control, 147% (Duncan‟s new multiple range 
test p<0.05). Data are presented in Table 18. 
Differences in treatment groups were not significant in the individual 
verification experiment (ANOVA F=19.63, df= 4, P=0.4603). However, Duncan‟s 
new multiple range test revealed animals fed HFCS had a 243% upregulation in 
RAMP3 expression. Sucrose and control did not differ. Glucose and fructose fed 
animals both showed significant downregulation by 35% and 93% respectively. 
Differences between glucose and fructose were significant (p<0.05). Data are 
presented in Table 18. 
 
Tumor Necrosis Factor (TNF-α) 
Results from the PCR array did not reveal any significant differences in TNF-
α expression when analyzed with ANOVA (F=3.87, df= 4, P=0.085). Duncan‟s new 
multiple range test however did reveal significant differences between glucose and 
HFCS and control (p<0.05). Glucose, upregulated TNF-α by 165%, differed from 
HFCS and control. Sucrose and fructose did not differ from any other experimental 
groups. Data are presented in Table 19. 
Results from the pooled verification were significant when analyzed with 




upregulated hypothalamic TNF-α as compared to control though they were not 
significantly different amongst themselves (glucose 148%, sucrose 167% and fructose 
167%) (Duncan‟s new multiple range test p<0.05). TNF-α expression in rats fed 
HFCS however did not differ from control (p>0.05). Data are presented in Table 19. 
ANOVA was not applied to the individual verification PCR data due to fact 
that the mean thresholds were higher than 36 cycles, suggesting that the existing 
message concentrations in these samples was too low for consideration. Data are 
presented in Table 19. 
 
Thyrotropin Releasing Hormone (TRH)  
ANOVA applied to the PCR array data revealed significant differences in 
TRH expression in experimental groups (ANOVA F=32.89, df= 4, P=0.0009). 
Subsequent post-hoc analyses (Duncan‟s new multiple range test) further revealed the 
greatest change in TRH expression was from consumption of HFCS that promoted a 
57% downregulation as compared to control (p<0.05). Glucose and sucrose also 
downregulated TRH by 45% and 23% respectively. By contrast, fructose 
consumption promoted an upregulation of 122% (p<0.05). Data are presented in 
Table 20. 
Pooled verification ANOVA analysis also revealed differences in 
experimental groups (ANOVA F=37.56, df= 4, P=0.0006). All treatment groups with 
the exception of HFCS were upregulated when compared to control. The greatest 
upregulation in TRH expression was that in animals given access to sucrose solutions 




sucrose fed rats had a 23% downregulation in TRH expression. Glucose and fructose 
also significantly upregulated TRH message by 386% and 372% respectively. Lastly, 
HFCS consumption resulted in the least change in message of 122% (p<0.05). Data 
are presented in Table 20. 
Because of time and resource limitations individual verification was not 
performed for TRH.  
 
Urocortin (UCN) 
Results from the ANOVA of PCR array data revealed that there were 
significant differences in treatment groups (ANOVA F=116.76, df= 4, P<0.0001). 
Further post-hoc analyses revealed that the only significant difference was an 111% 
upregulation of hypothalamic UCN by glucose consumption (p<0.05). The remaining 
groups did not differ from control. Data are presented in Table 21. 
ANOVA was not applied to the pooled or individual PCR data due to fact that 
the mean thresholds were higher than 36 cycles, suggesting that the existing message 













It is well accepted that there is an alarming obesity epidemic in this country. 
The obesity problem is particularly worrying not only in terms of human health and 
quality of life but also in terms of dollars spent on healthcare in the treatment of 
obesity related comorbidities. Obesity has become the nation‟s most preventable 
health problem (1, 2).  Despite it‟s prevalence, there is no known cure for this disease 
or consensus about how it develops. One hypothesis for the cause of obesity is that 
dietary intake patterns of Americans have significantly shifted over the past fifty 
years by including unprecedented amounts of refined sugar (4).    
The purpose of this experiment was to examine this hypothesis by evaluating 
how sugars affect the appetite regulatory center of the brain, the hypothalamus. 
Animals were given 24 hour access to either a dilute glucose, sucrose, HFCS, or 
fructose sugar solution. Intake of both chow and sugar was measured. Hypothalamic 
tissue was collected and changes in gene expression were measured using a RT-PCR 
array as well as traditional RT-PCR on pooled tissue samples (pooled verification) 
and individual rat samples (individual verification). 
 
Intake 
 Previous studies have shown that initial presentation of a sugar solution will 
result in rats consuming excess calories from sugar. Over time however this result 
washes out and total caloric intake returns to a level that resembles control (70, 74).  
These findings may suggest an explanation for our results that sugar fed animals all 




consumed the same amount of total calories and there were no differences in percent 
kcal from sugar for groups consuming fructose containing sugars (sucrose, HFCS, 
fructose). 
The rats in this experiment did not increase intake of glucose-fructose 
disaccharides (sucrose and HFCS) in such a way as to match the amount of fructose 
consumed in the fructose group. In other words rats did not have a threshold for 
fructose consumption and compensate by consuming 50% more sucrose or 45% more 
HFCS to match the total consumption of fructose in the fructose fed group. We 
applied the same model as Collier and Bolles did in their 1968 sugar dilution studies. 
Looking at intake of various sugar dilutions in rats, Collier and Bolles found that 
regardless of the type of sugar presented, rats will increase their intake of a dilute 
sugar so as to take in a certain threshold amount of total grams of sugar (75). In the 
current study, this model was applied to dilutions of fructose intake. For example, 
sucrose fed animals had a solution that was 50% less fructose than the fructose 
animals. Replicating Collier and Bolles‟ findings, there was not set level for fructose 
intake as animals consuming sucrose and HFCS, which have less fructose, consumed 
the same amount of total kcal from sugar. These findings also show that fructose 
having a sweeter taste than glucose did not impact intake. 
 
Plasma 
Fructose caused a significant and robust increase in triglycerides with only 24 




fructose feeding studies in rats and in humans (76, 77). The importance of this finding 
is that hypertriglyceridemia occurred with only 24 hour access to fructose.  
No differences in plasma insulin or glucose were observed, as all blood 
samples were collected under ad libitum feeding conditions.  
 
Gene expression 
By using the PCR array technique we were able to evaluate the effects of 
different sugars on multiple hypothalamic genes with a very fast turn over. As seen in 
Table 6, significant changes for glucose fed animals were only upregulations.  
We had also expected to see sucrose and HFCS fed animals to have similar 
results. Surprisingly, there were no genes with significant changes observed in both 
groups. Given that HFCS and sucrose only slightly vary in composition, it is unclear 
why results from intake of these sugars were not similar. The lack of a similar effect 
or a dose dependent effect demonstrates a limitation of the present analysis. In the 
future, this problem may be resolved with increasing the number of animals in each 
group and also running more replicates of the array assay.  
We selected genes for subsequent analyses (pooled and individual 
verifications) based on those with significant up or downregulation (1.5 fold change 
and above, or 0.5 fold change and below). From this list of significant genes we were 
able to select genes that had a known role in the regulation of CHO intake and 






Cholecystokinin (CCK) is an anorexogenic peptide that is expressed in both 
the small intestine and the brain. Expression of CCK results in short duration 
reduction of meal size (23). CCK is also important in the regulation of insulin.  
As shown here, glucose consumption results in significant upregulation of 
CCK. This has been observed in previous work in animals maintained on a high fat 
diet (27). The impact of glucose on CCK expression may be as a result of the 
interaction of CCK with insulin. Lo (2011) using CCK-KO mice, found that these 
animals had reduced insulin response. CCK is required for regulating both insulin 
secretion and glucose tolerance in mice on a high fat diet. Considering these findings, 
it is proposed that CCK is upregualated by glucose such that CCK can in turn 
stimulate insulin release. 
Alternatively, fructose consumption resulted in significant downregulation of 
CCK (if you exclude information from the individual analysis). This is a novel 
finding and has yet to be discussed in the literature. It is known that fructose and 
glucose are metabolized differently (Figure 2). Because CCK is anorectic and is 
upregulated by glucose but down regulated by fructose it illustrates how the 
differences the two sugars interact metabolically. It is also interesting to note that 
CCK is an anorectic peptide and fructose fails to upregulate it. This point suggests 





Corticotrophin Releasing Hormone 
Corticotropin-releasing hormone (CRH), also known as Corticotropin-
releasing factor (CRF) is an anorectic peptide secreted by neurosecretory cells of the 
parvocellular region of the periventricular nucleus (PVN) of the hypothalamus and 
carried via the portal system to the anterior lobe of the pituitary where it promotes 
ACTH production (30).  
Ulrich-Lai and colleagues evaluated the effect of sucrose on CRF expression. 
They found that daily limited access to a sucrose sweetened drink resulted in 
decreased CRH mRNA expression (33). In the present study however, sucrose did not 
differ from control in either the PCR array or the pooled verification. On the other 
hand, HFCS (the other disaccharide in this study) intake did significantly 
downregulate CRH message. Though the aforementioned study did not measure 
changes to CRH with HFCS consumption, it is unclear why in this study HFCS 
replicates the finding while sucrose does not.  
The literature also shows that when glucose decreases, CRH expression 
increases (21, 31, 32). However in the present study the effects of increased glucose 
rather than reduced glucose were measured. Although no changes in CRH expression 
in glucose fed animals were observed, in the future this could be examined by 
comparing animals that had been fasted and then given a dose of glucose, to animals 
that had only been fasted. Utilizing different doses of glucose would allow the 
examination of the amount of glucose required to reduce CRH expression back to 




Also, fructose, though not different from control, prevented the 
downregulation observed with HFCS. This is an interesting finding because it 
suggests a role of insulin in CRH expression. It should be mentioned that fructose 
does not initiate an insulin response, but HFCS does.  
In the future it will be interesting to evaluate changes in CRH expression in 
animals consuming fructose that have been administered insulin. This experiment will 




GH is thought to be an anorexogenic peptide that not only contributes to the 
regulation of energy expenditure but also growth. However, there is limited literature 
surrounding the effects of Growth Hormone (GH) on the regulation of energy balance 
and intake.  
Growth hormone is another anorectic protein whose expression was 
upregulated by glucose intake. As was discussed in the intake sections, giving rats 
access to sugar solutions and chow results in increased total caloric intake, and at the 
same time a significant reduction in daily chow intake. Given the upregulation of GH 
it could be suggested that GH is playing a role in suppressing chow intake but not 
sugar intake. Sugar solution intake might be spared the suppression as the result of 
increased dopamine activation of the reward pathway. 
We did not find any significant effects of fructose on GH and thus our results 




One possible explanation may be that in the Strauch study, fructose was administered 
IV.  
There has been interesting work done on the effects of fasting and obesity 
states on GH secretion (50). In the future it would be interesting to further explore the 
effects of both glucose and fructose on obese animals given only 24 hour access to 
these sugars. It could be predicted that glucose would be less able to increase GH 
expression due to changes in metabolic flexibility resulting from obesity.  
 
Receptor Activity Modifying Protein 3 
Receptor activity modifying protein 3 (RAMP3) is a G protein-coupled 
receptor (GPCR) accessory protein in the family of RAMP. One function of RAMP3 
is to interact with the calcitonin receptor to produce amylin receptor complexes. Once 
formed, these complexes allow binding of amylin to the receptor. Another function of 
RAMP3 is to complex with calcitonin receptor-like receptor (CLR) to form 
adrenomedullin receptors (15, 58). Because the RAMP family plays such an 
important role in the transport and modulation of GPCRs, there have been extensive 
pharmacological studies aimed at examining RAMPs as potential sites for modulating 
GPCRs for the sake of disease treatment. Though much is known about the function 
of this protein, little has been reported on the specific impact of RAMP3 in the 
control of intake and energy balance. 
In the present study, if individual analyses are excluded, RAMP3 was found to 
be upregulated by glucose and alternatively downregulated by HFCS and fructose. 




known that RAMP3 is involved in amylin processing. It is also known that CCK and 
amylin have similar metabolic actions such as slowing gastric emptying.  Because the 
trends in gene expression for RAMP3 are similar to those observed with CCK, 
upregulation by glucose and downregulation by fructose, it is reasonable to assume 
that sugars have the same implications on RAMP3 expression as they do on CCK. 
That is to say perhaps RAMP3, upstream on the amylin pathway, triggers the same 
metabolic consequences as CCK. 
 
Tumor Necrosis Factor 
Tumor Necrosis Factor-α (TNF-α) is an inflammatory cytokine found in the 
hypothalamus. TNF plays in active role in inflammation and obesity and is involved 
in lipid metabolism regulation, adipocyte differentiation, and insulin sensitivity (60). 
TNF has been shown to interact with well-known satiety signals including leptin. 
Huypens has proposed a model for TNF that suggests the gene has a role in the 
regulation of the inverse relationship between ADIPOQ and leptin (61).  
Glucose, sucrose, and fructose consumption all resulted in an upregulation of 
TNF expression in the hypothalamus. Recently much of the work surrounding 
possible causes of obesity has been centered on inflammation and the impact sugar 
has on inflammation (62). TNF is an important inflammatory cytokine and because 
sugar has been shown to cause inflammation, these results are as expected. However, 
it is unclear as to why HFCS did not result in upregulation as well. 
Wang suggests that once animals that have been made obese with a high fat 




return to levels of control (62). The importance of this finding here is that even if 
these animals were removed from the sugar diet they may still suffer from elevations 
of this inflammatory peptide. In the future a longer term study which examines TNF 
levels following removal of sugar access from sugar-induced obese rats may provide 
insight into this subject.  
 
Thyrotropin Releasing Hormone 
Thyrotropin- releasing hormone (TRH), also called Thyrotropin- releasing 
factor (TRF), is produced in the PVN of the hypothalamus and functions to stimulate 
the release of thyroid stimulating hormone and prolactin from the anterior pituitary.  
TRH is an anorectic hormone.  
 The mechanism of TRH action on appetite regulation is not yet fully 
understood (63).  Leptin has been found to have direct and indirect (through 
activating POMC neurons that in turn release αMSH to stimulate TRH) effects on 
stimulation of TRH synthesis (65).  
Compared to control, TRH gene expression is upregulated in animals given 
access to fructose. These results are consistent with the long-recognized role of 
fructose promoting increases in uric acid, leading to increased risk of gout (a disease 
associated with hypothyroidism) (78). 
NPY also acts on TRH as an inhibitor through activation of NPY receptors on 
the TRH neurons (66). Here however this association could not be evaluated because 











 Obesity has become such a significant public health concern that there is 
urgency to better understand its causes. Due to sugars‟ ability to alter hypothalamic 
appetite regulation, this research attempted to evaluate the hypothesis that increased 
intake of added sugars may be contributing to the obesity epidemic. This was a very 
well designed protocol as it looked at common disaccharides while also having the 
monosaccharaide controls. Many other studies examining HFCS fail to have fructose 
and/or  glucose control groups. This research has shed light onto many important 
effects of sugar consumption and also presented the opportunity for many other 
follow up experiments.  
 It is curious that the only significant changes in gene expression that were 
verified in all performed assays were changes in anorectic genes. However, it should 
be pointed out that there are fewer known orexogenic genes. Another interesting trend 
in gene expression is that in the glucose fed group, the only significant changes were 
those of upregulations. In other words, glucose intake only resulted in the 
upregulation of anorectic gene expression. This might be an indicator of how glucose 
metabolism evolved and how glucose, being a good source of calories, tells the body 
that enough calories have been taken in and eating can stop.  
 This research laid the groundwork for many other follow up studies. First of 
all, a longer term sugar feeding study would allow for the examination of changes in 
intake following adaptation to the novelty of the sugar solutions.  Laboratory rats will 
over eat sugar initially but will subsequently restore control-level total caloric intake. 




solutions and should show that intake of treatment groups will, over time, more 
closely resemble controls. Once intake is „leveled off,‟ evaluation of gene expression 
in the hypothalamus will provide insight into how gene expression changes with 
longer term access. Also, depending on the length of access, by the end of an 
extended feeding study the animals may become obese. It would be interesting to 
compare changes in hypothalamic gene expression between both the long term study 
obese animals with the present study lean animals. 
 With a longer term study it might also be interesting to provide animals with 
different doses of sugars and also take samples at more time intervals. Assuming 
animals are sacrificed and hypothalamic tissue analyzed throughout the study, the 
varied doses will allow for the examination of thresholds at which changes become 
significant. This would apply to humans who consume sugar sweetened beverages at 
different levels of consumption.  
While doing this long term study, or even in a short term study as this was, 
sampling plasma continuously would allow for a more real time analysis of change in 
plasma TG as well as glucose. In the present study, there were no changes observed 
in insulin and glucose. Continuous sampling would allow for the measure of these in 
as they respond to intake.  
Finally in future studies it would be interesting to examine changes in protein 
levels of the hypothalamic genes of interest. The fact that a gene is upregulated does 
not necessarily mean the protein will be expressed in greater amounts. Measuring 
changes in protein will allow for a complete examination of the impact of sugars on 







Plotted above are the average changes in intake of fructose (free and total) and HFCS 
over time (in years) as well as the average changes in the % of the population 
classified as either overweight or obese during that same period. (Adapted from Bray 
et al., 2004)  
Figure 1. Relationship between fructose intake and prevalence of 








Comparison of the metabolism of fructose and glucose. The red arrow indicates 
where fructose enters the liver cell via the GLUT5 transporter and feeds into the 
glycolysis pathway. Fructose has less control points and feeds directly into G3P 
(glucose-3-phosphate). The red box surrounds the results of the TCA cycle which is 
the formation of TG. Adapted from Johnson et al., 2009 (79). 





Sectioned rat brain showing region of tissue collected for measure of changes in gene 
expression. Area of collection is boxed in red. Regions include VMN, DMN, PVN, 
arcuate nucleus and median eminence. Adapted from Paxinos and Watson, 1986 (80). 










(°C) Sense Primer Anti-sense Primer 





ADRA2b NM_138505 114 53.5 TACTCTCATCATCCCTTTC 
ATGGAGGAGGTACAGAA
G 
AGRP XM_574228 97 57.6 
GAGTTCTCAGGTCTAAGT
CT GTGGATCTAGCACCTCTG 
APOA4 NM_012737 129 58.9 CTCCATACCAAAGTCTCC CTTGTTCAGGTCTTCCAG 





CCK NM_012829 133 53 
GCGTTTATTTATTAAGTC
C ATAGCATAGCAACATTAG 
CLPS NM_013139 83 58.9 CCTTGTTGTTCTGCTTGTA CGTCCTCCAGGTTGATAA 
CRH NM_031019 158 51 TGGAGATTATCGGGAAAT 
TACATCTTCTATGCTTCA
AG 





GAPDH NM_017008 92 56 TCCCATTCTTCCACCTTT 
TAGCCATATTCATTGTCA
TACC 
GH1 NM_001034848 88 51 
CAAGCAAACCTATGACA
A CTTCTTGAAGCAGGAGAG 
IAPP NM_012586 92 56.2 AACTTCTTGGTTCGCTCC TCTGCCACATTCCTCTTC 
LDHA NM_017025 112 54.2 
TTGTTGATGTCATAGAAG
A GCAGTCACACTATAATCT 





RAMP3 NM_020100 109 54.6 CAAGGTCATCTGGAAGGT 
GACTCCTAACAACTCCAT
TC 










TRH NM_013046 75 59.7 
AAAGACATTGAAGCTGA
AGAGAGG GGGGTGCTGTCGTTTGTG 
UCN NM_019150 75 60.6 AGCAGAACCGCATCATAT AAAGGGTCAAGGCTTTCT 
 
Primers were designed using Beacon Designer 7 unless otherwise noted in Methods 
section. TaOpt determined empirically. 
  




  Control Glucose Sucrose HFCS Fructose 











Average body weight in grams. Rats were weighed just prior to sacrifice. Averages 
that share a common superscript are not different from one another (p>0.05). 





Grams Control Glucose Sucrose HFCS Fructose 
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Rats were given 24 hour access to a sugar solution as well as water and chow. Control 
animals had access to chow and water only. Averages of each measurement that share 
a common superscript are not different from one another (p>0.05). 
 
  






































Changes in plasma TG, glucose and insulin following 24 hour access to sugar 
solutions.  Plasma was collected from trunkal blood at the time of sacrifice. 
Triglycerides were measured with the Dimension clinical chemistry system with a 
Flex reagent cartridge (Siemens Healthcare Diagnostics, Newark, DE) using a Dade 
Behring Dimension Xpand automated system. Glucose was measured enzymatically 
(Smith-Kline Beecham Laboratories, Brentford, Middlesex, UK). Insulin was 
measured by ELISA (LINCOplex; LINCO Research, St. Charles, MO). Averages of 
each measurement that share a common superscript are not different from one another 
(p>0.05). 
  




































N 5 8 5 5 8 
 
Multiple housekeepers were analyzed and the one with the least variation between 
experimental groups and the lowest Ct was selected. Presented are the cycle 
thresholds (Ct) of RT-PCR using each housekeeper primer set and pooled 
hypothalamic cDNA from each experimental group. Primer sequence can be found in 
Table 1. Averages of each measurement that share a common superscript are not 
different from one another (p>0.05). 
 
 







Symbol Name Glucose Sucrose HFCS Fructose 
Adipoq Adiponectin 3.54 1.01 1.33 2.33 
Adra2b Adrenergic, alpha-2B-, receptor 1.16 0.86 0.35 0.48 
Agrp Agouti related protein homolog (mouse) 1.26 0.96 1.98 1.05 
Apoa4 Apolipoprotein A-IV 0.86 0.28 1.15 0.58 
Cck Cholecystokinin 1.98 1.23 1.39 0.63 
Clps Colipase, pancreatic 1.56 1.48 1.56 0.98 
Crh Corticotropin releasing hormone 0.87 0.76 0.48 1.21 
Drd1a Dopamine receptor D1A 0.83 0.70 2.07 1.08 
Gh1 Growth hormone 1 3.27 1.01 1.20 1.09 
Iapp Islet amyloid polypeptide 2.00 1.11 1.20 2.28 
Il1a Interleukin 1 alpha 1.19 1.75 0.95 1.01 
Il6 Interleukin 6 1.12 1.51 0.83 0.92 
Ins2 Insulin 2 0.66 0.97 0.47 0.80 
Nmu Neuromedin U 1.11 0.38 1.30 1.08 
NPY Neuropeptide Y 1.13 1.03 2.27 1.01 
Ntrk1 Neurotrophic tyrosine kinase, receptor, 1 1.20 0.94 1.20 1.85 
Ramp3 Receptor activity modifying protein 3 1.32 1.09 0.44 0.52 
Tnf Tumor necrosis factor 1.65 1.39 1.04 1.25 
Trh Thyrotropin releasing hormone 0.55 0.77 0.43 1.22 
Ucn Urocortin 4.08 1.01 1.44 1.09 
Presented in the right hand columns of this table are the fold changes in appetite 
regulating genes.  Highlighted in yellow or red are those changes that were 
considered “significant.”  In order to be considered “significant” a fold change 
needed to be downregulated (red) by 50% or more (fold change < 0.5) or upregulated 
(yellow) by 150% or more (fold change > 1.5) following sugar access. Fold change 
was calculated Fold change was calculated as 2^(-ddCt).  
  





Results of PCR array analysis of ADIPOQ expression in the hypothalamus of animals 
given 24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array 
(PARN-017A, SABiosciences) was used to obtain estimates of changes to ADIPOQ. 
PCR array was performed on pooled hypothalamic tissue from all animals in each 
group. Averages of each measurement that share a common superscript are not 
different from one another (p>0.05).  
  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 37.12 33.54 36.01 34.88 33.90 
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  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 32.69 32.84 32.93 34.48 33.87 
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Results of two analyses of ADRA2b expression in the hypothalamus of animals given 
24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-
017A, SABiosciences) was used to obtain initial estimates of changes to ADRA2b. 
Pooled verification was then performed using RT-PCR and primers designed in 
house. Primer sequences for pooled verification assays are found in Table 1. PCR 
array and pooled verification assays were performed on pooled hypothalamic tissue 
from all animals in each group. Averages of each measurement that share a common 
superscript are not different from one another (p>0.05). 
 
  
Table 8. Summary of analyses used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 26.59 26.62 26.67 25.87 26.64 










 N 5 8 5 5 8 
Pooled 
verification 











 N 5 8 5 5 8 
Individual 
verification 
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Results of three analyses of AGRP expression in the hypothalamus of animals given 
24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-
017A, SABiosciences) was used to obtain initial estimates of changes to AGRP. 
Pooled verification, followed by individual verification, was then performed using 
RT-PCR and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual assays are presented. Averages 
of each measurement that share a common superscript are not different from one 
another (p>0.05). 
* Mean threshold cycle was above cutoff value of 36 cycles.  As a result, data from 
this group was not included. 
  
Table 9. Summary of the three analyses used to determine the effect of sugar solution 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 31.81 32.39 33.68 31.87 32.73 










 n 5 8 5 5 8 
 
Results of PCR array analysis of APOA4 expression in the hypothalamus of animals  
given 24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array 
(PARN-017A, SABiosciences) was used to obtain estimates of changes to APOA4. 
PCR array was performed on pooled hypothalamic tissue from all animals in each 
group. Averages of each measurement that share a common superscript are not 
different from one another (p>0.05). 
Table 10. Summary of analysis used to determine the effect of sugar solution access 





Results of three analyses of CCK expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to CCK. Pooled 
verification, followed by individual verification, was then performed using RT-PCR 
and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual assays are presented. Averages 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 24.19 23.57 23.92 23.98 24.98 
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Pooled 
verification 
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Individual 
verification 
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Table 11. Summary of the three analyses used to determine the effect of sugar 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 32.77 32.92 32.49 32.39 32.22 










 N 5 8 5 5 8 
 
Results of PCR array analysis of CLPS expression in the hypothalamus of animals  
given 24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array 
(PARN-017A, SABiosciences) was used to obtain estimates of changes to CLPS. 
PCR array was performed on pooled hypothalamic tissue from all animals in each 
group. Averages of each measurement that share a common superscript are not 
different from one another (p>0.05). 
 
  
Table 12. Summary of analysis used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 27.03 27.59 27.45 28.34 26.88 
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Results of two analyses of CRH expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to CRH. Pooled 
verification was then performed using RT-PCR and primers designed in house. 
Primer sequences for pooled verification assays are found in Table 1. PCR array and 
pooled verification assays were performed on pooled hypothalamic tissue from all 
animals in each group. Averages of each measurement that share a common 
superscript are not different from one another (p>0.05). 
 
  
Table 13. Summary of analyses used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 28.87 29.51 29.41 28.08 28.87 










 n 5 8 5 5 8 
Pooled 
verification 











 n 5 8 5 5 8 
Individual 
verification 
Ct 38.96 39.32 39.22 38.27 39.02 
n 4 4 4 4 4 
 
Results of three analyses of DRD1a expression in the hypothalamus of animals given 
24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-
017A, SABiosciences) was used to obtain initial estimates of changes to DRD1a. 
Pooled verification, followed by individual verification, was then performed using 
RT-PCR and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual verification assays are 
presented. Fold change is not presented for individual verification because Ct was 
greater than 35 and thus not „significant.‟ Averages of each measurement that share a 
common superscript are not different from one another (p>0.05). 
  
Table 14. Summary of the three analyses used to determine the effect of sugar 




  Control Glucose Sucrose HFCS Fructose 





















 n 5 8 5 5 8 
Pooled 
verification 











 n 5 8 5 5 8 
Individual 
verification 
Ct 38.95 33.66 38.80 37.56 38.29 
n 4 4 4 4 4 
 
Results of three analyses of GH1 expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to GH1. Pooled 
verification, followed by individual verification, was then performed using RT-PCR 
and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual verification assays are 
presented. Fold change is not presented for individual verification because Ct was 
greater than 35 and thus not „significant.‟ Averages of each measurement that share a 
common superscript are not different from one another (p>0.05).  
Table 15. Summary of the three analyses used to determine the effect of sugar 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 35.82 34.37 35.42 35.75 33.93 
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Pooled 
verification 
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Results of two analyses of IAPP expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to IAPP. Pooled 
verification was then performed using RT-PCR and primers designed in house. 
Primer sequences for pooled verification assays are found in Table 1. PCR array and 
pooled verification assays were performed on pooled hypothalamic tissue from all 
animals in each group. Averages of each measurement that share a common 
superscript are not different from one another (p>0.05). 
 
  
Table 16. Summary of analyses used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 25.80 25.98 25.77 24.88 25.90 
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Pooled 
verification 
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Individual 
verification 
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Results of three analyses of NPY expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to NPY. Pooled 
verification, followed by individual verification, was then performed using RT-PCR 
and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual assays are presented. Averages 
of each measurement that share a common superscript are not different from one 
another (p>0.05).  
Table 17. Summary of the three analyses used to determine the effect of sugar 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 25.99 25.95 25.88 27.43 27.05 
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Pooled 
verification 
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Individual 
verification 
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Results of three analyses of RAMP3 expression in the hypothalamus of animals given 
24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-
017A, SABiosciences) was used to obtain initial estimates of changes to RAMP3. 
Pooled verification, followed by individual verification, was then performed using 
RT-PCR and primers designed in house. Primer sequences for pooled and individual 
verification assays are found in Table 1. PCR array and pooled verification assays 
were performed on pooled hypothalamic tissue from all animals in each group. 
Individual verification was performed on individual hypothalamic tissue from four 
rats from each group. Averages of the four individual assays are presented. Averages 
of each measurement that share a common superscript are not different from one 
another (p>0.05).  
Table 18. Summary of the three analyses used to determine the effect of sugar 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 32.76 32.40 32.30 32.96 32.55 
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Pooled 
verification 
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Results of two analyses of TNF-α expression in the hypothalamus of animals given 
24 hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-
017A, SABiosciences) was used to obtain initial estimates of changes to TNF-α. 
Pooled verification was then performed using RT-PCR and primers designed in 
house. Primer sequences for pooled verification assays are found in Table 1. PCR 
array and pooled verification assays were performed on pooled hypothalamic tissue 
from all animals in each group. Averages of each measurement that share a common 
superscript are not different from one another (p>0.05). 
 
  
Table 19. Summary of analyses used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 25.23 26.46 25.63 26.71 25.07 
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Pooled 
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Results of two analyses of TRH expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to TRH. Pooled 
verification was then performed using RT-PCR and primers designed in house. 
Primer sequences for pooled verification assays are found in Table 1. PCR array and 
pooled verification assays were performed on pooled hypothalamic tissue from all 
animals in each group. Averages of each measurement that share a common 
superscript are not different from one another (p>0.05). 
 
  
Table 20. Summary of analyses used to determine the effect of sugar solution access 




  Control Glucose Sucrose HFCS Fructose 
PCR Array Ct 35.83 35.50 33.34 34.74 35.78 










 n 5 8 5 5 8 
Pooled 
verification 
Ct 37.01 33.99 36.95 36.48 36.45 
n 5 8 5 5 8 
 
Results of two analyses of UCN expression in the hypothalamus of animals given 24 
hour access to sugar solutions. Rat Obesity RT² Profiler™ PCR Array (PARN-017A, 
SABiosciences) was used to obtain initial estimates of changes to UCN. Pooled 
verification was then performed using RT-PCR and primers designed in house. 
Primer sequences for pooled verification assays are found in Table 1. PCR array and 
pooled verification assays were performed on pooled hypothalamic tissue from all 
animals in each group. Fold change is not presented for pooled verification because 
Ct was greater than 35 and thus not „significant.‟ Averages of each measurement that 
share a common superscript are not different from one another (p>0.05). 
 
Table 21. Summary of analyses used to determine the effect of sugar solution access 





Appendix A. List of genes on RT
2
 PCR array  
 
Unigene GeneBank Symbol Description Gene Name 
Rn.202559 NM_016989 Adcyap1 Adenylate cyclase 
activating polypeptide 1 
Pacap 
Rn.88408 NM_133511 Adcyap1r1 Adenylate cyclase 











Rn.104556 NM_207587 Adipor1 Adiponectin receptor 1 - 
Rn.101984 NM_001037979 Adipor2 Adiponectin receptor 2 - 
Rn.10296 NM_138505 Adra2b Adrenergic, alpha-2B-, 
receptor 
- 




Rn.137597 NM_033650 Agrp Agouti related protein 
homolog (mouse) 
- 
Rn.15739 NM_012737 Apoa4 Apolipoprotein A-IV Apo-AIV, 
ApoA-IV, 
apoAIV 
Rn.53846 NM_031351 Atrn Attractin - 
Rn.11266 NM_012513 Bdnf Brain-derived 
neurotrophic factor 
MGC105254 
Rn.86415 NM_152845 Brs3 Bombesin-like receptor 3 - 
Rn.11378 NM_016994 C3 Complement component 
3 
- 







Rn.10062 NM_053816 Calcr Calcitonin receptor - 
Rn.89164 NM_017110 Cartpt CART prepropeptide Cart 
Rn.9781 NM_012829 Cck Cholecystokinin - 
Rn.10184 NM_012688 Cckar Cholecystokinin A 
receptor 
Cck-ar 




Appendix A. List of genes on RT
2
 PCR array (continued) 
 
Unigene GeneBank Symbol Description Gene Name 
Rn.89774 NM_012784 Cnr1 Cannabinoid receptor 1 
(brain) 
SKR6R 
Rn.6067 NM_013166 Cntf Ciliary neurotrophic 
factor 
- 
Rn.55036 NM_001003929 Cntfr Ciliary neurotrophic 
factor receptor 
- 
Rn.10349 NM_031019 Crh Corticotropin releasing 
hormone 
CRF 
Rn.10499 NM_030999 Crhr1 Corticotropin releasing 
hormone receptor 1 
- 
Rn.24039 NM_012546 Drd1a Dopamine receptor D1A D1a, Drd-1, 
Drd1 
Rn.87299 NM_012547 Drd2 Dopamine receptor D2 - 
Rn.8929 NM_033237 Gal Galanin prepropeptide Galn 
Rn.10213 NM_012958 Galr1 Galanin receptor 1 Galnr1 
Rn.54383 NM_012707 Gcg Glucagon GLP-1 
Rn.11225 NM_172092 Gcgr Glucagon receptor MGC93090 
Rn.146351 NM_001034848 Gh1 Growth hormone 1 Gh, 
RNGHGP 





Rn.42103 NM_021669 Ghrl Ghrelin/obestatin 
prepropeptide 
- 
Rn.74241 NM_032075 Ghsr Growth hormone 
secretagogue receptor 
- 




Rn.138127 NM_139193 Prlhr Prolactin releasing 
hormone receptor 
Gpr10, Uhr-1 
Rn.10822 NM_031758 Mchr1 Melanin-concentrating 
hormone receptor 1 
Gpr24, Mch-
1r, Slc1 
Rn.10930 NM_133570 Grp Gastrin releasing peptide - 
Rn.10316 NM_012706 Grpr Gastrin releasing peptide 
receptor 
- 
Rn.7628 NM_013179 HcRt Hypocretin orexin-A 






Appendix A. List of genes on RT
2
 PCR array (continued) 
 
Unigene GeneBank Symbol Description Gene Name 
Rn.81032 NM_017018 Hrh1 Histamine receptor H 1 Hisr 
Rn.9935 NM_012765 Htr2c 5-hydroxytryptamine 




Rn.11394 NM_012586 Iapp Islet amyloid polypeptide - 
Rn.12300 NM_017019 Il1a Interleukin 1 alpha IL-1 alpha 
Rn.9869 NM_031512 Il1b Interleukin 1 beta - 
Rn.9758 NM_013123 Il1r1 Interleukin 1 receptor, 
type I 
- 
Rn.9873 NM_012589 Il6 Interleukin 6 ILg6, Ifnb2 
Rn.1716 NM_017020 Il6r Interleukin 6 receptor IL6R1, Il6ra 
Rn.962 NM_019129 Ins1 Insulin 1 - 
Rn.989 NM_019130 Ins2 Insulin 2 - 
Rn.9876 NM_017071 Insr Insulin receptor - 
Rn.44444 NM_013076 Lep Leptin OB, obese 
Rn.9891 NM_012596 Lepr Leptin receptor Fa 
Rn.215838 NM_001025270 Mc3r Melanocortin 3 receptor - 
Rn.130371 XM_218815 Nmb Neuromedin B RGD1562710 
Rn.89709 NM_012799 Nmbr Neuromedin B receptor NMB-R 
Rn.47720 NM_022239 Nmu Neuromedin U - 
Rn.54457 NM_023100 Nmur1 Neuromedin U receptor 1 Gpr66 
Rn.9714 NM_012614 Npy Neuropeptide Y NPY02, 
RATNPY, 
RATNPY02 




Rn.90070 NM_012576 Nr3c1 Nuclear receptor 
subfamily 3, group C, 
member 1 
GR, Gcr, Grl 
Rn.39098 NM_021589 Ntrk1 Neurotrophic tyrosine 
kinase, receptor, type 1 
Trk 
Rn.60814 NM_001102381 Nts Neurotensin - 
Rn.200149 NM_001108967 Ntsr1 Neurotensin receptor 1 Ntsr 





Appendix A. List of genes on RT
2
 PCR array (continued) 
 
Unigene GeneBank Symbol Description Gene Name 
Rn.10118 NM_013071 Oprm1 Opioid receptor, mu 1 MORA, 
Oprm, 
Oprrm1 
Rn.1129 NM_030996 Sigmar1 Sigma non-opioid 
intracellular receptor 1 
Oprs1 
Rn.108195 NM_139326 Pomc Proopiomelanocortin Pomc1, 
Pomc2 
Rn.9753 NM_013196 Ppara Peroxisome proliferator 
activated receptor alpha 
PPAR 
Rn.23443 NM_013124 Pparg Peroxisome proliferator-
activated receptor gamma 
- 
Rn.19172 NM_031347 Ppargc1a Peroxisome proliferator-
activated receptor 
gamma, coactivator 1 
alpha 
Ppargc1 









Rn.48672 NM_020100 Ramp3 Receptor (G protein-
coupled) activity 
modifying protein 3 
- 
Rn.11286 NM_031767 Sort1 Sortilin 1 Nt3, Nts3 
Rn.34418 NM_012659 Sst Somatostatin SS-14, SS-
28, Smst 
Rn.42915 NM_012719 Sstr1 Somatostatin receptor 1 Gpcrrna 



















Appendix A. List of genes on RT
2 
PCR array (continued) 
 
Unigene GeneBank Symbol Description Gene Name 
Rn.22 NM_013046 Trh Thyrotropin releasing 
hormone 
THR, TRH01 
Rn.9962 NM_013047 Trhr Thyrotropin releasing 
hormone receptor 
- 
Rn.10190 NM_019150 Ucn Urocortin - 






Rn.973 NM_001007604 Rplp1 Ribosomal protein, large, 
P1 
MGC72935 






Rn.92211 NM_173340 Rpl13a Ribosomal protein L13A - 
Rn.107896 NM_017025 Ldha Lactate dehydrogenase A Ldh1 
Rn.94978 NM_031144 Actb Actin, beta Actx 
N/A U26919 RGDC Rat Genomic DNA 
Contamination 
RGDC 
N/A SA_00104 RTC Reverse Transcription 
Control 
RTC 
N/A SA_00104 RTC Reverse Transcription 
Control 
RTC 
N/A SA_00104 RTC Reverse Transcription 
Control 
RTC 
N/A SA_00103 PPC Positive PCR Control PPC 
N/A SA_00103 PPC Positive PCR Control PPC 
N/A SA_00103 PPC Positive PCR Control PPC 
 
List of genes on RT
2
 PCR array (SABioscience, PARN-017A). Utilizing RT-PCR 
analysis, each array profiles the expression of 84 genes related to obesity, including 
genes that code for orexigenic peptides, hormones, and receptors, anorectic peptides, 
hormones, and receptors, and central and peripheral signaling molecules related to 




Appendix B. Results of RT
2
 PCR array  
 
 Fold Change (comparing to control group) 
Symbol Fructose Glucose HFCS Sucrose 
Adcyap1 1.0182 1.0345 1.0852 1 
Adcyap1r1 0.7479 0.7366 0.6704 0.7873 
Adipoq 2.3311 3.5406 1.3315 1.014 
Adipor1 0.97 1.1439 0.9781 0.9727 
Adipor2 0.9801 1.0526 0.8111 0.9428 
Adra2b 0.48 1.1559 0.347 0.8586 
Adrb1 1.0324 1.1599 1.2167 0.8322 
Agrp 1.0541 1.2649 1.9834 0.9593 
Apoa4 0.5767 0.8639 1.1511 0.2784 
Atrn 0.97 0.9069 0.8055 0.8526 
Bdnf 1.0468 1.2388 1.2861 1.0497 
Brs3 1.0989 0.9356 1.0056 1.0905 
C3 0.9019 1.2218 0.9679 1.2702 
Calca 0.8712 0.76 0.694 1.1134 
Calcr 1.1736 0.76 1.0777 1.1408 
Cartpt 0.8213 0.9389 1.1157 1.0497 
Cck 0.6289 1.9779 1.3928 1.2269 
Cckar 1.1736 0.7366 0.8111 0.8766 
Clps 0.9767 1.5572 1.5616 1.4794 
Cnr1 1.1181 0.8061 1.2596 0.917 
Cntf 0.9835 1.0063 0.8456 0.9526 
Cntfr 1.0578 1.0203 0.8876 0.9044 
Crh 1.2066 0.873 0.484 0.7552 
Crhr1 1.0253 1.0417 0.9221 0.8265 
Drd1a 1.0837 0.8259 2.0677 0.6974 
Drd2 1.2449 1.3186 1.4671 0.9862 
Gal 1.08 0.8202 1.1794 1.0353 
Galr1 1.08 0.7895 0.8397 0.9593 
Gcg 1.0875 1.287 1.2 1.3708 
Gcgr 1.1736 0.9324 0.935 0.9862 
Gh1 1.0875 3.2693 1.2 1.014 
Ghr 1.0725 0.852 1.0231 1.0353 
Ghrl 1.0147 0.9292 0.7361 0.8351 
Ghsr 1.2492 0.855 1.0126 0.8858 
Glp1r 1.0762 0.9069 1.1551 0.8675 
Prlhr 0.95 0.6547 0.5657 0.9395 
Mchr1 1.0007 0.9356 0.9382 0.933 





Appendix B. Results of RT
2
 PCR array (continued) 
 
 Fold Change (comparing to control group) 
Symbol Fructose Glucose HFCS Sucrose 
Grpr 1.19 0.8699 0.8693 1.1212 
HcRt 0.6139 0.7392 1.1392 0.8888 
Hcrtr1 1.0725 0.8287 0.7889 0.9013 
Hrh1 1.0147 0.8033 0.7972 0.8467 
Htr2c 1.1142 0.9356 0.8111 1.014 
Iapp 2.2831 1.9986 1.2 1.1096 
Il1a 1.0147 1.1925 0.9546 1.7471 
Il1b 1.2932 0.9487 0.8426 1.1975 
Il1r1 1.1655 1.0563 0.9781 1.0317 
Il6 0.9176 1.1243 0.8282 1.5105 
Il6ra 1.2277 1.1802 1.2083 1.3472 
Ins1 0.9938 1.0973 0.7621 0.9363 
Ins2 0.7989 0.6616 0.4707 0.9727 
Insr 0.9767 0.8005 0.8938 0.9202 
Lep 1.0875 1.287 1.2 1.014 
Lepr 0.7906 1.2959 0.9849 1.0981 
Mc3r 1.0762 0.8944 1.0629 0.9559 
Nmb_predicted 1.08 1.0168 1.0592 0.9593 
Nmbr 0.7797 1.06 0.6988 0.8858 
Nmu 1.0837 1.105 1.3041 0.3776 
Nmur1 1.0989 1.0822 1.0852 1.0461 
NPY 1.0112 1.1321 2.2705 1.0317 
NPY1r 0.9801 0.9653 0.831 1.1057 
Nr3c1 0.905 0.9389 0.8139 0.9559 
Ntrk1 1.8545 1.1966 1.2041 0.9428 
Nts 1.2932 0.9586 1.1511 1.244 
Ntsr1 1.0951 1.4379 0.9382 1.0943 
Oprk1 0.9633 0.76 0.8282 0.9298 
Oprm1 0.8386 0.989 0.5795 0.9931 
Oprs1 1.1455 0.952 0.9 0.9526 
Pomc 1.0837 0.8639 1.1471 0.8066 
Ppara 1.1416 1.0822 0.7889 1.0681 
Pparg 1.0504 1.3604 0.726 1.1567 
Ppargc1a 0.9733 1.0098 0.9 0.895 
Ptpn1 1.0762 1.0238 1.0446 1.0681 
Pyy 1.0182 0.5963 0.632 1.0461 
Ramp3 0.5216 1.3186 0.4407 1.0943 





Appendix B. Results of RT
2
 PCR array (continued) 
 
 Fold Change (comparing to control group) 
Symbol Fructose Glucose HFCS Sucrose 
Sst 1.1181 0.8287 0.831 1.0035 
Sstr1 1.1219 0.8316 1.0303 0.8039 
Thrb 1.0147 0.7732 1.1672 0.8123 
Tnf 1.2535 1.646 1.041 1.3899 
Trh 1.2193 0.5506 0.4302 0.7711 
Trhr 1.0913 1.105 0.9849 0.9931 
Ucn 1.0875 4.0812 1.4369 1.014 
Ucp1 0.9633 0.784 0.8633 0.8438 
Rplp1 0.9801 0.9993 0.9986 0.9965 
Hprt1 0.9369 1.0028 1.1119 1.0389 
Rpl13a 1.0651 0.9686 0.9063 1.0792 
Ldha 0.9337 1.0133 1.0021 0.8766 
Actb 1.0951 1.0168 0.9917 1.021 
RGDC 1.0875 1.287 1.2 1.014 
RTC 0.9467 0.8491 0.9917 0.9862 
RTC 0.9938 0.8852 1.0056 0.9965 
RTC 1.0504 0.876 1.0629 1.0389 
PPC 1.0432 1.2825 1.2816 1.057 
PPC 1.2406 1.3232 1.35 1.0497 
PPC 1.1818 1.305 1.2466 1.0943 
 
Complete results of findings from RT
2
 PCR array (SABioscience, PARN-017A). 
Presented is the average fold change from two replicate experiments. PCR array was 
performed on pooled hypothalamic tissue from all animals in each group. Fold 
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